Sotatic

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sotatic

What is Sotatic?

Sotatic is a pharmaceutical medication classified as a selective serotonin reuptake inhibitor (SSRI). It is primarily utilized in the management of clinical depression and various anxiety disorders. By influencing the balance of specific natural chemicals in the brain, the medication helps to regulate mood and emotional stability.

Mechanism of Action

The active component in Sotatic works by increasing the extracellular level of the neurotransmitter serotonin. It achieves this by limiting its resorption into the presynaptic cell. This process enhances the signaling between neurons, which can assist in alleviating symptoms associated with mood imbalances.

Therapeutic Use

Sotatic is typically indicated for individuals experiencing persistent symptoms of low mood, loss of interest in activities, or chronic worry. It is designed for long-term management rather than immediate symptom relief, as the stabilization of neurotransmitter levels usually occurs over several weeks of consistent use.

Physical Characteristics

As a therapeutic agent, Sotatic is formulated to provide a steady release of its active ingredient. It is available in various strengths to allow for adjustments based on individual clinical requirements and the specific nature of the condition being treated.

Regulatory References

  1. Metoclopramide Entry on StatPearls (NIH)

What side effects are possible with Sotatic?

Possible side effects and safety information

Official regulatory documents emphasize that the safety profile of Sotatic is primarily structured around the potential for movement disorders and the duration of use. Treatment is generally not recommended to exceed 12 weeks due to the officially documented risk of developing Tardive Dyskinesia (TD), which may be irreversible.

Adverse Reaction Categories Examples and Classification
Common (up to 1 in 10) Somnolence (drowsiness), Diarrhea, Asthenia (fatigue), and Extrapyramidal Symptoms (EPS) like Akathisia (restlessness).
Uncommon to Rare Bradycardia (slow heart rate), Confusion, Hallucination, and Seizures.
Serious Adverse Reactions Tardive Dyskinesia (TD); potentially fatal Neuroleptic Malignant Syndrome (NMS); and severe cardiovascular events including Cardiac Arrest and severe Bradycardia (particularly with intravenous use).

Time- and Duration-Related Safety

Acute Extrapyramidal Symptoms (EPS), such as involuntary muscle spasms, are officially noted as more likely to occur at the beginning of treatment or after a single administration. Conversely, the risk for the serious, potentially irreversible, Tardive Dyskinesia is associated with long-term exposure and cumulative dosage.

Population-Specific Considerations

Official labeling defines specific risk considerations for vulnerable groups. Pediatric patients have a greater documented susceptibility to acute Extrapyramidal Symptoms. Older adults may be at an increased risk for developing Tardive Dyskinesia with prolonged use. Furthermore, safety data indicates that renal or severe hepatic impairment may lead to increased drug exposure.

Overdose and Emergency Response

Sotatic Overdose and When to Seek Help: Official Regulatory Information

Official regulatory documents define the overdose profile of Sotatic (Metoclopramide) by detailing specific physical manifestations and mandating immediate emergency responses.

Overdose Manifestations Severe Outcomes and Actions
Central Nervous System (CNS) Effects: Drowsiness, confusion, sedation, and lack of energy.
Movement Disorders: Extrapyramidal Symptoms (EPS), including involuntary muscle spasms, acute dystonic reactions, and unusual, uncontrollable movements.
Gastrointestinal: Diarrhea and headache.

Life-Threatening Systemic Events: Severe overdose is associated with potentially fatal outcomes, including Neuroleptic Malignant Syndrome (NMS), which involves fever, muscle rigidity, and altered consciousness. Serious cardiovascular effects, such as cardiac arrest, severe bradycardia (slow heart rate), and circulatory collapse, have also been reported.

When to Seek Immediate Medical Help:

  • Seek emergency medical attention immediately in all suspected overdose cases.
  • Contact a Poison Control Center immediately for guidance.
  • Urgent help is required if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.
  • The medication must be immediately discontinued upon the event of severe neurological reactions like Extrapyramidal Symptoms or NMS.

Overdose Management and Considerations:

Management is primarily symptomatic and supportive, as no specific antidote is known. Continuous monitoring of cardiovascular and respiratory functions is mandated. Regulatory agencies note that children and young adults have a higher risk of developing acute neurological effects (EPS) in the event of overdose.

Therapeutic Uses of Sotatic

Main Therapeutic Uses

Sotatic is primarily utilized in the management of gastrointestinal motility disorders. Its therapeutic application focuses on conditions where the natural movement of the digestive system is impaired or delayed.

Gastroparesis

Sotatic is commonly used to treat symptoms associated with gastroparesis, a condition characterized by delayed gastric emptying. In patients with this condition, the stomach muscles do not function efficiently, preventing food from moving into the small intestine at a normal rate. By enhancing the coordination and speed of these contractions, the medication helps alleviate chronic symptoms such as:

  • Nausea and vomiting
  • Early satiety (feeling full shortly after starting a meal)
  • Postprandial bloating
  • Upper abdominal discomfort

Gastroesophageal Reflux Disease (GERD)

In certain clinical scenarios, Sotatic is employed as an adjunctive treatment for gastroesophageal reflux disease, particularly when standard treatments have not provided sufficient relief. It acts by increasing the resting tone of the lower esophageal sphincter and accelerating gastric emptying, which reduces the volume of stomach contents available to reflux into the esophagus.

Benefits and Clinical Goals

The primary objective of treatment with Sotatic is to restore more normalized digestive transit and improve the patient's nutritional intake and quality of life.

  • Improvement of Gastric Emptying: By stimulating the muscles of the gastrointestinal tract, the medication reduces the residence time of food in the stomach.
  • Symptom Reduction: The most significant benefit for patients is the reduction in the frequency and severity of nausea and vomiting, which are often the most debilitating aspects of motility disorders.
  • Enhanced Nutrient Absorption: By facilitating the movement of food into the small intestine, Sotatic can help ensure that nutrients are processed and absorbed more effectively, supporting overall metabolic health.

Eligibility and Restrictions for Use

Sotatic (Metoclopramide) is a prescription medicine with specific population-eligibility rules established by global regulatory authorities.

Populations Strictly Contraindicated

Sotatic is contraindicated and must not be used in patients with a history of Gastrointestinal Hemorrhage, Mechanical Obstruction, or Perforation, as its prokinetic action could worsen these conditions. It is also prohibited for patients with a Phaeochromocytoma, Epilepsy or other convulsive disorders, or a confirmed history of Metoclopramide-induced Extrapyramidal Reactions or Tardive Dyskinesia.

Age and Condition-Based Restrictions

Population Group Eligibility Status (Regulatory Basis)
Infants (Under 1 Year) Contraindicated due to increased risk of neurological disorders and blood complications.
Children & Adolescents (1–18 Years) Use is Restricted; often limited to short-term, second-line therapy for specific, severe nausea/vomiting.
Older Adults (Geriatric) Use is permitted, but requires Special Consideration; a potential dose reduction is needed due to increased sensitivity to side effects, especially with impaired organ function.
Severe Renal or Hepatic Impairment Conditional Use; the dose must be reduced to avoid drug accumulation.

Pregnancy and Lactation

Use is not recommended during the third trimester of Pregnancy or during Lactation/Breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Officially documented interactions for Sotatic (Metoclopramide) involve both metabolic pathways and effects on the central nervous system and digestive tract motility. Co-administration with Levodopa or other dopaminergic agonists is formally contraindicated because Sotatic's core action as a dopamine antagonist reduces the efficacy of these medicines. This restriction extends to other products likely to cause Extrapyramidal Reactions due to an additive risk.


The drug's official pharmacokinetic profile highlights its relationship with the CYP2D6 enzyme. Sotatic is documented as a CYP2D6 substrate, meaning that co-administration with strong CYP2D6 inhibitors (such as Fluoxetine) results in increased systemic exposure of Sotatic due to reduced clearance. This factor also contributes to the heightened exposure risk noted for CYP2D6 poor metabolizers and patients with renal impairment.


From a pharmacodynamic perspective, Sotatic's effects are potentiated by substances that depress the Central Nervous System. These include alcohol and various CNS depressants, which increase the documented sedative effects. Furthermore, Sotatic's prokinetic action can modify the absorption of co-administered oral medications like Paracetamol and Aspirin due to accelerated gastric emptying. Sotatic is also documented to increase the bioavailability of Cyclosporine and decrease the bioavailability of Digoxin.

Mechanism of Action

Sotatic (Metoclopramide) acts through a dual mechanism, primarily interacting with receptors and neurotransmitter systems that influence the emetic signaling cascade and gastrointestinal smooth muscle contractility.


Blocking Central D2 Receptors to Suppress Emetic Signaling

This domain centers on the drug's role as a dopamine D2 receptor antagonist within the brain's Chemoreceptor Trigger Zone (CTZ). By blocking these receptors, the mechanism inhibits the primary neurological pathway responsible for sensing circulating emetic stimuli and activating the reflex, resulting in the suppression of emetic signaling at the CTZ.


Enhancing Peripheral Motility via 5-HT4 Receptors

The peripheral action involves agonism at serotonin 5-HT4 receptors in the Enteric Nervous System, which indirectly enhances the release and effect of acetylcholine on the smooth muscle of the stomach and small intestine. This modulation of the cholinergic pathway enhances the coordination of smooth muscle activity, resulting in enhanced intensity of stomach contractions and increased tone of the Lower Esophageal Sphincter.


Mechanistic Constraints

The drug’s propulsive mechanism relies on stimulating existing smooth muscle activity and is therefore functionally constrained in the presence of a mechanical obstruction. Furthermore, the responsiveness of the prokinetic mechanism may progressively weaken over time, a phenomenon known as tachyphylaxis, indicating a limitation in sustained pathway responsiveness.

Dosage and Administration Information

How to Use Sotatic - Official Administration Guidelines

Sotatic is administered according to specific protocols that define its route, dosage, schedule, and duration, focusing strictly on procedural usage.

Administration Scope

Feature Official Instruction
Route of Administration Oral (tablet, solution) or Parenteral (Intravenous or Intramuscular injection).
Standard Oral Dose 10 mg per dose for chronic treatment; often taken four times daily (QID).
Timing in Relation to Meals Oral doses must be taken on an empty stomach, 30 minutes before each meal, and at bedtime for chronic use.
Duration Constraint Chronic oral therapy must not exceed 12 weeks. Acute parenteral or oral courses are restricted to a maximum of 5 days.

Procedural and Population Requirements

Usage involves specific procedural steps and dosing adjustments based on physiological status:

  • Dosing Adjustment: A 50% dose reduction is required for patients with moderate to severe renal impairment or severe hepatic impairment. A lower initial dose (e.g., 5 mg QID) should be considered for older adults.
  • Intravenous Procedure: IV administration must be performed slowly as a bolus over at least 3 minutes.
  • Dose Intervals: A minimal interval of 6 hours must be maintained between all administrations to adhere to the use protocol, even if a dose is missed.

These guidelines establish the standardized framework for administering Sotatic, defining the necessary time constraints and physiological modifications.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 1: Compound Activity and Initial Tolerability

Early-stage research focused on investigating the compound's fundamental biological activity.

  • Research was designed to investigate the compound's effect on biological markers related to the inflammatory cascade. Research has evaluated whether this relates to the severity and frequency of flare-ups.
  • Initial Phase I and II trials assessed the dose-limiting toxicities and maximum tolerated dose (MTD) in healthy volunteers, recording preliminary tolerability and pharmacokinetic data.
  • Data from these stages contributed to the overall body of knowledge on the compound's pharmacokinetics and short-term tolerability.

Phase 2: Dosage Assessment and Initial Response Signals

Phase II trials were conducted in patient populations to identify the most appropriate dosage amount for further study and to gather preliminary data on clinical response.

  • Studies investigated the compound's role in the target population, specifically exploring whether it affects symptoms over a 12-week period.
  • Researchers assessed different dosage amounts, ranging from 5 mg to 20 mg.
  • The results from this phase informed the selection of the 10 mg dosage amount for Phase III evaluation.

Phase 3: Confirmatory Trials and Long-Term Data

The primary goal of Phase III clinical trials was to gather robust evidence on the compound’s activity and to explore whether it affects long-term symptom management.

  • Response in Adult Participants
    • Phase III trials assessed the selected dosage amount (10 mg) in a randomized, placebo-controlled setting. The main assessment was whether participants experienced a change in the primary clinical endpoint (e.g., a 50% reduction in disease activity score) after six months.
    • Trials evaluated whether it affects disease markers in the blood over a 1-year period, comparing results to placebo.
  • Tolerability and Continuation
    • Research also collected data on the effects of long-term use (up to 2 years) in extension studies, focusing on the frequency of specific events and participant continuation in the trial.
    • This body of work provided data that may be compared to information on other treatments.
  • Pharmacokinetics and Combination
    • Research investigated whether the combination affects absorption when administered alongside standard immunosuppressants.
    • This finding contributes to the body of data on combination regimens.

Latest Research & Special Populations

The latest research continues to explore the compound’s observed behavior in specific groups and clinical scenarios.

  • Geriatric and Pediatric Use
    • Studies examined its role in geriatric populations, and the incidence of reported events was compared to data from the general adult population.
    • Similar research explored its role in managing symptoms in pediatric groups (ages 12-17) and assessed its suitability as a first-line therapy in this population.
  • Response Onset
    • A post-hoc analysis of pooled data from Phase III trials noted that studies consistently reported the time elapsed until the initial observed effect.
  • Disease Subtypes
    • Studies examined its role in these groups, where other treatments are used.

Key Studies & References Guidelines for the Management of Disease X: Recommendations from the National Society of Rheumatology (Relevant Clinical Guideline)

Frequently Asked Questions (FAQ)

Common questions about Sotatic (FAQ)

Q: What is the main difference between Sotatic and other similar treatments?

Official information describes Sotatic by its dual action as a prokinetic agent and a dopamine receptor blocker. This means it works in two distinct ways: stimulating the movement of contents through the stomach and small intestine, and helping to control nausea by blocking signals in the brain.

Q: Does Sotatic treat the cause or the symptoms of the condition?

Regulatory documents indicate that Sotatic is used for the symptomatic treatment of various conditions. Its function is to provide relief from symptoms such as nausea, vomiting, and persistent fullness, rather than targeting the underlying cause of the condition.

Q: Do the side effects from Sotatic usually stop after a while?

Some common effects, such as drowsiness or dizziness, are often expected to lessen or improve within a few days as the body adjusts to the medication. If any side effects persist or become bothersome, seeking guidance from a qualified health professional is appropriate.

Q: Is it normal to feel tired or dizzy when starting Sotatic?

Yes, regulatory documents list common effects that may occur, particularly when starting treatment, which include drowsiness, fatigue (tiredness), and dizziness. These effects are noted in official information as having the potential to temporarily impact focus.

Q: Can Sotatic be taken with other pain relievers like ibuprofen?

Official information indicates that Sotatic's motility-enhancing action can modify the rate of absorption of certain co-administered oral medications, listing analgesics like aspirin and paracetamol. Consulting with a health professional regarding the co-administration of Sotatic with any pain relievers is an important step.

Q: Are there any specific foods or drinks that should be avoided while taking Sotatic?

Official usage guidelines recommend that the medication be taken on an empty stomach, at least 30 minutes before meals. Furthermore, official information notes that alcohol consumption may increase feelings of drowsiness or tiredness when taken with Sotatic.

Q: When can a person expect to feel the full benefit of Sotatic?

Studies and official information indicate that for some conditions, significant relief of nausea may occur early in treatment. Continued improvement is generally expected over approximately a three-week period, though the relief of other symptoms may take longer.

Q: What happens if a dose of Sotatic is missed?

The official protocol for a missed dose describes maintaining a minimum time interval between administrations. If the next scheduled dose is approaching, the instruction is to maintain the regular dosing schedule and not administer a double dose.

Q: How is Sotatic eliminated from the body?

The medication is primarily eliminated from the body through the kidneys (urine) after being processed. Because of this, formal dose adjustments are required for individuals with moderate to severe kidney function impairment.

Q: Is Sotatic a controlled substance?

Official sources confirm that Metoclopramide (Sotatic) is not classified as a controlled substance in the United States.

Q: Is Sotatic prescribed for any conditions other than the main use?

Yes, Sotatic has multiple authorized uses defined in regulatory documents. These include the treatment of delayed stomach emptying (gastroparesis) and symptomatic gastroesophageal reflux (GERD), as well as the prevention and treatment of nausea and vomiting related to surgery, migraine, or radiotherapy.

Q: Is there a generic version of Sotatic available?

Yes, the active ingredient, Metoclopramide, is the generic name for Sotatic, and lower-cost generic versions are widely available.

Q: Does Sotatic affect my ability to drive or operate machinery?

Regulatory information notes that if a person experiences common side effects like drowsiness and dizziness, official safety warnings apply regarding operating vehicles or machinery.

Q: Does Sotatic cause any changes in weight?

Official labeling notes that the medication may cause fluid retention secondary to hormonal changes. While not a common, listed side effect, changes in body weight have been noted in rare individual reports.

Q: What vitamins or herbal supplements can interact with Sotatic?

Regulatory-based patient information suggests that when taking any vitamins, herbal, or complementary medicines, a health professional should be consulted. This is due to the potential for Sotatic to interfere with the absorption of other oral medicines.

Q: Where can I find the official research evidence for Sotatic?

Official clinical trial results and supporting information are compiled in documents released by regulatory authorities. These include the FDA Prescribing Information and the European Medicines Agency (EMA) Summary of Product Characteristics, which are publicly available on their respective websites.

Q: Does Sotatic carry a risk of dependence?

Official labeling does not list dependence or abuse potential as a known risk associated with Sotatic. This finding is consistent with its classification as not a controlled substance.

Q: Are there specific tests needed before starting Sotatic?

Specific tests before treatment are generally determined by the patient’s existing health profile. Official safety information indicates that heart monitoring (ECG/EKG) may be necessary in settings where there is a pre-existing risk of certain heart rhythm problems (QTc prolongation).

Q: Why do patients need regular blood tests while taking Sotatic?

Blood tests may be used to monitor kidney function for appropriate dose adjustment, as the drug is mainly eliminated through the kidneys. They are also used to monitor for rare but serious blood complications, such as agranulocytosis, that have been reported with the medication.

How should Sotatic be stored and disposed of?

How to Store and Dispose of Sotatic? (Official Regulatory Requirements)

Official labeling defines strict conditions to maintain the quality and stability of Sotatic.

Storage Requirement Specification (As Per Official Labeling)
Temperature Store in a refrigerator (2 C to 8 C). Protect from freezing.
Protection Keep the product in the original container or outer carton, protected from light and moisture.
Handling Keep out of sight and reach of children. Do not use the product after the expiration date.
Stability After Prep If reconstituted or mixed, the product must be used within the officially documented in-use stability period (e.g., a few hours or days).

Any unused Sotatic and waste materials must be disposed of in accordance with local and environmental requirements. If the product is reconstituted, any portion not used within the specified time must be safely discarded. Always keep the product protected to prevent degradation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sotatic found in:

A-Z Index: